Identification of cytochrome P450 isoform involved in the metabolism of YM992, a novel selective serotonin re-uptake inhibitor, in human liver microsomes

Xenobiotica

Volumn 30, Issue 5, 2000, Pages 503-513

  Noguchi, K ^a   Mera, A ^a   Watanabe, T ^a   Higuchi, S ^a   Chiba, K ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[(7 FLUORO 4 INDANYL)OXY]METHYL]MORPHOLINE; ALPHA NAPHTHOFLAVONE; ANTIBODY; CYTOCHROME P450; ISOSAFROLE; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; COMPETITIVE INHIBITION; DRUG COMPETITION; DRUG METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; METABOLIC INHIBITION; METABOLIC RATE; PROTEIN LOCALIZATION; YEAST;

EID: 0033870089     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982500237505     Document Type: Article

References (25)

1. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes
2. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes
3. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes
4. Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450
5. Human cytochrome P450: Problems and prospects
6. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics
7. Catalytic selectivity of human cytochrome P-450: Relevance to drug metabolism and toxicity
8. In vitro techniques for studying drug metabolism
9. Oxidation of quinidine by human liver cytochrome P-450
10. Biochemical profile of YM992, a novel selective serotonin reuptake inhibitor with 5-HT(2A) receptor antagonistic activity
11. Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes
12. Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man
13. Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIP
14. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes
15. The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations
16. Non-specific binding to microsomes: Impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol
17. Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole
18. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity
19. Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8
20. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
21. Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe
22. Human liver CYP2B6-catalyzed hydroxylation of RP-73401
23. Pharmacological studies on YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT(2A) receptor antagonistic activity
24. Theophylline metabolism in human liver microsomes: Inhibition studies
25. Isozyme- and species-specific susceptibility of cDNA expressed CYP1A P-450s to different flavonoids